Clinical outcomes of Ahmed glaucoma valve implantation in pediatric glaucoma. 2019

Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
1 Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

To evaluate the outcomes of Ahmed glaucoma valve implantation in refractory primary congenital glaucoma as well as primary procedure in aphakic glaucoma. In this retrospective study, medical records of patients who underwent Ahmed glaucoma valve implantation for refractory glaucoma and aphakic glaucoma were reviewed. Primary outcome measures were the surgical success defined as intraocular pressure ≤21 mm Hg and decreased ≥20% and no secondary glaucoma surgery. Secondary outcome measures were the number of glaucoma medications, complications, best corrected visual acuity, and intraocular pressure. A total of 62 eyes of refractory primary congenital glaucoma patients (group 1) and 33 eyes of aphakic glaucoma patients (group 2) were included in our study. Mean follow-up was 51 ± 33 months in group 1 and 49 ± 41 months in group 2 (p = 0.82). The cumulative probability of success was 90% in both groups at the first year; however, the success rate was 52.5% in group 1 and 71.5% in group 2 at 5 years' follow-up visit. In group 1, the mean intraocular pressure ± standard deviation was 33.1 ± 8.6 mm Hg at the baseline and decreased to 17.1 ± 5.3 mm Hg at 1 year and 18.5 ± 6.4 at 3 years postoperatively (all p's < 0.001). Corresponding values for group 2 were 28.9 ± 6.1, 15.2 ± 4.6, and 16.0 ± 5.9 mm Hg, respectively (all p's < 0.001). The baseline number of glaucoma medications was 3 ± 0.7 that decreased to 2 ± 0.8 at final follow-up (p = 0.02). Ahmed glaucoma valve implantation has a moderate success rate in the management of refractory primary congenital glaucoma with an increased chance of tube-related complications. The surgical success rate is higher in case of primary Ahmed glaucoma valve implant for aphakic glaucoma with acceptable safety profile.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006871 Hydrophthalmos Congenital open-angle glaucoma that results from dysgenesis of the angle structures accompanied by increased intraocular pressure and enlargement of the eye. Treatment is both medical and surgical. Buphthalmos
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
September 2018, Journal of glaucoma,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
March 2008, Clinical ophthalmology (Auckland, N.Z.),
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
January 2021, Journal of glaucoma,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
January 2022, Ophthalmology. Glaucoma,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
June 2009, Eye (London, England),
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
November 2017, American journal of ophthalmology,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
December 2016, Acta clinica Croatica,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
November 2023, Biomedicines,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
August 2005, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus,
Mohammad Pakravan, and Hamed Esfandiari, and Shahin Yazdani, and Azadeh Doozandeh, and Zahra Dastborhan, and Ebrahim Gerami, and Bahareh Kheiri, and Parastou Pakravan, and Mehdi Yaseri, and Kiana Hassanpour
February 2024, International ophthalmology,
Copied contents to your clipboard!